AstraZeneca PLC (AZN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

AstraZeneca ( AZN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.0%. By the end of trading, AstraZeneca rose $0.78 (1.2%) to $62.95 on average volume. Throughout the day, 2,357,275 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1,827,600 shares. The stock ranged in a price between $62.49-$63.04 after having opened the day at $62.58 as compared to the previous trading day's close of $62.17. Other companies within the Health Care sector that increased today were: Chelsea Therapeutics International ( CHTP), up 91.7%, Agios Pharmaceuticals ( AGIO), up 18.6%, Kindred Biosciences ( KIN), up 16.0% and Amarin Corporation ( AMRN), up 15.9%.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $75.0 billion and is part of the drugs industry. The company has a P/E ratio of 11.9, below the S&P 500 P/E ratio of 17.7. Shares are up 4.7% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates AstraZeneca a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Pain Therapeutics ( PTIE), down 14.3%, Oramed Pharmaceuticals ( ORMP), down 13.1%, iBio ( IBIO), down 11.2% and Rexahn Pharmaceuticals ( RNN), down 10.3% , were all laggards within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

CEOs Are Dropping Like Flies

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting